Abstract: Disclosed is an apparatus for treating containers with a transport device which transports the containers to be treated along a predetermined transport path, wherein said transport device has a rotatable transport carrier at which a plurality of treatment stations for treating the containers is arranged, wherein the apparatus has a clean room within which the containers are treated in a predetermined manner, and with a sealing device which seals said clean room from an environment, wherein said sealing device has a reservoir which can be filled with a liquid medium, and with a sensor device for measuring a filling level of said liquid medium at least indirectly. The sensor device is arranged in a supply line which can be brought into flow connection with the reservoir.

Abstract: This invention relates to extracellular protein-protein interactions and their possible therapeutic uses. More particularly, this invention describes the interaction between Draxin, particularly fragments binding to ?-Netrins comprising SEQ ID NO.:1, 2 or 3, and variants thereof, with ?-Netrins, and the use of this interaction to disrupt ?-Netrin/Netrin receptor interactions. The invention also relates to diagnostic and/or therapeutic uses of Draxin or fragments or variants thereof, as well as to an antibody against Draxin inhibiting binding of Draxin to ?-Netrins. Further, the invention relates to fragments of ?-Netrins, in particular Draxin-binding Netrin1-fragments comprising SEQ ID NO.: 51 and variants thereof, as well as to an antibody against ?-Netrins inhibiting binding of ?-Netrins to Netrin receptors.

Abstract: This invention relates to extracellular protein-protein interactions and their possible therapeutic uses. More particularly, this invention describes the interaction between Draxin, particularly fragments binding to ?-Netrins comprising SEQ ID NO.:1, 2 or 3, and variants thereof, with ?-Netrins, and the use of this interaction to disrupt ?-Netrin/Netrin receptor interactions. The invention also relates to diagnostic and/or therapeutic uses of Draxin or fragments or variants thereof, as well as to an antibody against Draxin inhibiting binding of Draxin to ?-Netrins. Further, the invention relates to fragments of ?-Netrins, in particular Draxin-binding Netrin1-fragments comprising SEQ ID NO.: 51 and variants thereof, as well as to an antibody against ?-Netrins inhibiting binding of ?-Netrins to Netrin receptors.

Abstract: This invention relates to extracellular protein-protein interactions and their possible therapeutic uses. More particularly, this invention describes the interaction between Draxin, particularly fragments binding to ?-Netrins comprising SEQ ID NO.: 1, 2 or 3, and variants thereof, with ?-Netrins, and the use of this interaction to disrupt ?-Netrin/Netrin receptor interactions. The invention also relates to diagnostic and/or therapeutic uses of Draxin or fragments or variants thereof, as well as to an antibody against Draxin inhibiting binding of Draxin to ?-Netrins. Further, the invention relates to fragments of ?-Netrins, in particular Draxin-binding Netrin1-fragments comprising SEQ ID NO.: 51 and variants thereof, as well as to an antibody against ?-Netrins inhibiting binding of ?-Netrins to Netrin receptors.